Thomas Joly, MD
Ophthalmology · Norfolk, VANPI 1093709156
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,612 of the $95,210 with a category attached, or 81.5%. Amgen accounts for 96.9% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $26,388, more than ten times the $240 reported in 2019. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $364.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$92K
- Mallinckrodt Hospital Products Inc.$847
- NEW World Medical,inc.$238
- AbbVie$209
- ANI Pharmaceuticals, Inc.$198
- Bausch & Lomb Americas Inc.$172
- plus $1K from 25 others
What the payments were for
- Consulting fees$6,3007%
- Speaking & faculty fees$77,61282%
- Travel & lodging$3,4654%
- Food & beverage$7,7078%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 153 | $92,215 |
| Mallinckrodt Hospital Products Inc. | 35 | $847 |
| NEW World Medical,inc. | 3 | $238 |
| AbbVie(2 entities) | 7 | $209 |
| ANI Pharmaceuticals, Inc. | 8 | $198 |
| Bausch & Lomb Americas Inc. | 5 | $172 |
| Merz Pharmaceuticals, LLC | 6 | $166 |
| Galderma Laboratories, L.p. | 1 | $150 |
| Sun Pharmaceutical Industries Inc. | 7 | $132 |
| Stryker | 1 | $121 |
| Alcon | 5 | $98 |
| Regeneron Healthcare Solutions, Inc. | 3 | $81 |
| AstraZeneca | 1 | $69 |
| Biotissue Holdings Inc. | 3 | $59 |
| Rayner Intraocular Lenses Limited | 2 | $52 |
| Harrow Eye, LLC | 2 | $47 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
| Shire North American Group Inc | 2 | $41 |
| Aerie Pharmaceuticals, Inc. | 2 | $34 |
| Novartis | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Dompe US, Inc. | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Thea Pharma Inc. | 1 | $18 |
| Alimera Sciences, Inc. | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$89,124
- NA$121
- MEDPOR TITAN$121
- ENVISTA ENVY$112
- ACTHAR$106
How this compares
$95,210 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TepezzaTeprotumumab-Trbw | 18 | $1,042,240 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 406 | $4,860 |
| ErythromycinErythromycin Base | 81 | $780 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $233 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 96 | $229 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $112 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTepezza | $92,215 | $1,042,24018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Stephen ScoperNorfolk$88K
- Kapil KapoorNorfolk$64K
- Albert CheungNorfolk$23K
- Samantha DewundaraNorfolk$19K
- Arielle SpitzeNorfolk$10K
- Rohit AdyanthayaNorfolk$6K
- Ethnie JonesRichmond$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.